Page 4 - Expanded Access Protocol News Today

Relief Therapeutics Holding AG: Relief Reports 2020 Financial Results and Provides Business Update Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update. "The past year has been an incredibly productive and rewarding one for all of us at Relief," said Raghuram (Ram) ...

Press release content from Accesswire. The AP news staff was not involved in its creation.

Search jobs 20-Jan-2021 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Mergers & Acquisitions 20.01.2021 / 07:00 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil Geneva, Switzerland...

Relief Therapeutics Holding AG: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil Relief"), a biopharmaceutical company with its lead compound RLF-100 TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH (" AdVita"), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatme...

Search jobs 30-Dec-2020 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study 30.12.2020 / 07:00 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure Geneva, Switzerland and Radnor, Pa, USA, December 30, 2020 - RELIEF THERAPEUTICS Holdi...

Share this article Share this article RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ("Relief") today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ (previously RLF-100 TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. E...

TMCnet News Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors [December 28, 2020] Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors – Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of ... Hutchison China MediTech LimitedDecember 28, 2020 GMT – Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptab...

Share: Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ("Chris") L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets. Mr. Stijnen is a highly experienced pharmaceut...

EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Personnel Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer 21.12.2020 / 07:00   Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ("Chris") L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the ma...